Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

Benzinga · 2d ago
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $10 to $8.